Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

45 results
  1. ... of 95 to 109 mm Hg, after a placebo washout period, to receive placebo or one of six ... maintenance phase, each patient entered a four-week placebo washout phase. Patients who had been randomly assigned to ...
  2. NLM Digital Collections - Modulator treatments for cystic fibrosis : effectiveness and value 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, April 27, 2020
    ... 4.4 (0 to without appropriate 18.3) washout Placebo: 7.3 (5.2 to 8.2) Difference ... between) 98.5 (6.4) difference (p-value) washout for 4 −2.22 (p=0.0097) weeks, and 150mg placebo every 12 hours for 4 weeks OR (2) ...
  3. NLM Digital Collections - Modulator treatments for cystic fibrosis : effectiveness and value : final evidence report ... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, June 7, 2018
    ... four- weeks, and 150mg Mean, percentage value) week washout placebo every 12 hours points (SD) −2.22 (p= ... twice daily, BMI Ivacaftor: 83.33 28-day washout period, Mean, kg (SD) Placebo: 79.97 (1) 22.7 (6.96) ©Institute ...
  4. ... failed an active treatment and withdrew during the placebo washout phase, the com- bined response rate was 76. ...
  5. ... 2 week baseline–4 weeks of drug or placebo–1 week washout–4 weeks of Limitations to generalizability: This sample ...
  6. NLM Digital Collections - Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia : effectiveness and value ... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 22, 2017
    ... 17.8) followed by 4 (combined w/ prior placebo disorder/mood disorder, n (%) weeks washout group) 2) 61 (64.9)/33 (35.1) ... 7 (9.6) 2) 2.4 VE and Washout periods 2) 47.2 (11.2) 3) 2.2 2) VBZ 40 mg/day, n=97 3) 47.6 (13.6) (combined w/ prior placebo group) Male, n (%) 1) 34 (68.0) 3) ...
  7. NLM Digital Collections - Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis : ... 
    Publication: Boston, MA : Institute for Clinical and Economic Review, December 2 2016
    ... doses of brodalumab URIs (≥5% in any or placebo DLQI: HADS-A (treatment group): Exclusion: A washout difference, after 1) 8.2, 2) 8.1, 3) 6.4 period was required NR imputation): for patients receiving PsA (%): 1) -1.3, 2) -1.5 ... supplementary p<0.001 appendix) Previous biologics (%): HADS- ...
  8. NLM Digital Collections - Mavacamten for hypertrophic cardiomyopathy : effectiveness and value : final evidence report .... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, November 16, 2021
    ... but partially recovered to LVEF 50% during the washout period. Three patients on mavacamten and three patients on placebo temporarily discontinued due to changes in QT interval. ...
  9. NLM Digital Collections - Abuse-deterrent formulations of opioids : effectiveness and value : final evidence report 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 8, 2017
    ... oxycodone 4) 73.7 (14.9) 20mg or placebo in a double- 5) 75.4 (16.8) blind, crossover with 24-hr 6) 52.7 (13.4) washout between. *p<0.0001 vs. IR oxycodone Intact ...
  10. ... Pulse rate was recorded at each clinic visit. Placebo Period The pretreatment BP and the compliance of the patient were determined during the prerandomization period. Following a drug washout period of 4 weeks, if patients were on ...
first · previous · 1 · 2 · 3 · 4 · 5 · next · last